Enanta Pharmaceuticals Inc (ENTA) : Krensavage Asset Management scooped up 24,401 additional shares in Enanta Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 906,930 shares of Enanta Pharmaceuticals Inc which is valued at $21,231,231.Enanta Pharmaceuticals Inc makes up approximately 7.34% of Krensavage Asset Management’s portfolio.
Other Hedge Funds, Including , Clinton Group Inc sold out all of its stake in ENTA during the most recent quarter. The investment firm sold 10,476 shares of ENTA which is valued $245,243. Glassman Wealth Services sold out all of its stake in ENTA during the most recent quarter. The investment firm sold 3,580 shares of ENTA which is valued $83,772.Cable Hill Partners reduced its stake in ENTA by selling 187 shares or 90.78% in the most recent quarter. The Hedge Fund company now holds 19 shares of ENTA which is valued at $418.Diam Ltd. reduced its stake in ENTA by selling 3,527 shares or 7.49% in the most recent quarter. The Hedge Fund company now holds 43,575 shares of ENTA which is valued at $957,779. Enanta Pharmaceuticals Inc makes up approx 0.01% of Diam Ltd.’s portfolio. Financial Architects Inc sold out all of its stake in ENTA during the most recent quarter. The investment firm sold 74 shares of ENTA which is valued $1,608.
Enanta Pharmaceuticals Inc opened for trading at $22.42 and hit $23.24 on the upside on Monday, eventually ending the session at $22.44, with a gain of 0.27% or 0.06 points. The heightened volatility saw the trading volume jump to 1,07,729 shares. Company has a market cap of $427 M.
On the company’s financial health, Enanta Pharmaceuticals Inc reported $-0.06 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.09. The company had revenue of $14.00 million for the quarter, compared to analysts expectations of $13.95 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 EPS.
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV) as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program the Company is developing agonists of the farnesoid X receptor or FXR that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC another disease of the liver that can result in liver damage liver failure or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir ABT-493 EDP-239 ABT-494 and EDP-494.